Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Aspirin and immune boosters could help fight prostate cancer before surgery

NCT ID NCT03899987

First seen May 05, 2026 · Last updated Jun 22, 2026 · Updated 6 times

Summary

This phase 2 trial tests whether giving a combination of enteric-coated aspirin, rintatolimod, and interferon-alpha 2b before prostate cancer surgery can boost the immune system's attack on tumors. The study involves 12 men with localized prostate cancer who are scheduled for surgery. The main goal is to see if these drugs increase cancer-fighting immune cells in the tumor.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

enteric-coated aspirin, rintatolimod, and interferon-alpha 2b

What this could lead to

If successful, this could point toward a new pre-surgery treatment that helps the immune system fight prostate cancer and lowers the chance of it coming back.

What could go wrong

This is a very small early-phase trial with only 12 participants, so results may not apply broadly. The drugs may cause side effects like flu-like symptoms or bleeding risks from aspirin.

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.